BP368

Gliclazide

British Pharmacopoeia (BP) Reference Standard

• Synonym(s): 1-(3-Azabicyclo[3.3.0]oct-3-yl)-3-p-tolylsulphonylurea
• Empirical Formula (Hill Notation): C₁₅H₂₁N₃O₃S
• CAS Number: 21187-98-4
• Molecular Weight: 323.41
• EC Number: 244-260-5
• MDL number: MFCD00409893
• UNSPSC Code: 12352125
• NACRES: NA.24

Properties

• grade: pharmaceutical primary standard
• API family: gliclazide
• form: crystalline powder
• shelf life: limited shelf life, expiry date on the label
• manufacturer/tradename: BP
• mp: 163-169 °C (lit.)
• application(s): pharmaceutical; pharmaceutical small molecule
• format: neat
• storage temp.: 2-8°C
• SMILES string: Cc1ccc(cc1)S(=O)(=O)NC(=O)NN2CC3CCCC3C2
• InChI: 1S/C15H21N3O3S/c1-11-5-7-14(8-6-11)22(20,21)17-15(19)16-18-9-12-3-2-4-13(12)10-18/h5-8,12-13H,2-4,9-10H2,1H3,(H2,16,17,19)
• InChI key: BOVGTQGAOIONJV-UHFFFAOYSA-N

Description

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Gliclazide BP Reference standard, intended for use in laboratory tests only as specifically prescribed in the British Pharmacopoeia.

Also used in monographs such as:

Gliclazide Tablets

Used in the treatment of non-insulin dependent diabetes mellitus (NIDDM).

Biochem/physiol Actions

Oxidative modification of low-density lipoprotein (LDL) plays an important role in vascular dysfunction associated with diabetes mellitus. Gliclazide is a second-generation sulfonylurea with free-radical-scavenging activity. Incubation of human aortic smooth muscle cell (HASMC) with native human LDL (100 μg/mL) in the presence of increasing concentrations of gliclazide (1 to 10 μg/mL) resulted in a dose-dependent decrease in HASMC-mediated LDL oxidation. Exposure of HASMCs to gliclazide (1 to 10 μg/mL) and native LDL (100 μg/mL) also led to a dose-dependent decrease in oxidized LDL-induced human monocyte adhesion to HASMCs. In addition, incubation of HASMCs with gliclazide dramatically reduced the ability of oxidized LDL to stimulate the proliferation of these cells. Finally, treatment of HASMCs with gliclazide resulted in a marked decrease in oxidatively modified LDL-induced monocyte chemoattractant protein (MCP)-1 and human heat shock protein 70 (HSP 70) expression, both at the gene and protein levels. These results show that gliclazide, at concentrations in the therapeutic range (5 to 10 μg/mL), is effective in vitro in reducing vascular smooth muscle cell (VSMC) dysfunction induced by oxidatively modified LDL. Administration of gliclazide to type 2 diabetic patients could form part of the strategy for the prevention and management of diabetic cardiovascular diseases

Packaging

Unit quantity: 200 mg. Subject to change. The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity please visit British Pharmacopoeia

Other Notes

Sales restrictions may apply.

Safety Information

• Pictograms: GHS07
• Signal Word: Warning
• Hazard Statements: H302
• Precautionary Statements: P301 + P312 + P330
• Hazard Classifications: Acute Tox. 4 Oral
• Storage Class Code: 11 - Combustible Solids
• WGK: WGK 2
• Flash Point(F): Not applicable
• Flash Point(C): Not applicable